Source: International Congress 2018 – Primary care management of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Hallensleben (Leiden, Netherlands), J. Biewenga (Leiden, Netherlands), J. van Boven (Groningen, Netherlands), N. Chavannes (Leiden, Netherlands). REducing Delay through edUcation on eXacerbations (REDUX) in patients with COPD. 919

Member's Comments

No comment yet.

Related content which might interest you: Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE) Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Co-morbidity and hospitalization rate in patients (pts) with acute exacerbation (AE) of COPD Source: International Congress 2015 – Different data in COPD Year: 2015 Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014 The severity of anxiety in COPD patients (pts) Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP) Source: International Congress 2014 – Clinical presentations Year: 2014 Heterogeneity inside group D COPD patients: About 827 cases Source: International Congress 2016 – Biomarkers and phenotypes of COPD Year: 2016 Non invasive ventilation (NIV) in COPD exacerbation (AECOPD) in elderly patients Source: Annual Congress 2010 - Noninvasive ventilation in the acute patient: outcome and pathophysiology Year: 2010 PP307 – The role of microalbuminuria (MAB) in patients admitted for an Acute COPD Exacerbation (AECOPD) Source: ERS Lung Science Conference 2021 Year: 2021 Outcomes in patients with COPD during a 3 year follow-up Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Mental disorders in patients (pts) with COVID-19 pneumonia:comparison with COPD exacerbation Source: Virtual Congress 2021 – Long COVID - 19 Year: 2021 Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Indacaterol/glycopyrronium (IND/GLY) is cost-effective compared with salmeterol/fluticasone (SFC) in Swedish chronic obstructive pulmonary disease (COPD) patients Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017 Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 COPD Assessment Test (CAT) has a positive relationship with exacerbations in COPD patients. Source: International Congress 2019 – Clinical implications of COPD management Year: 2019 Impulse-oscillometry (IOS) differences in asthma and COPD patients, and healthy-subjects Source: International Congress 2014 – Airways: reversibility and responsiveness Year: 2014 LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 TIOSPIR®: Large scale trial of tiotropium Respimat® vs HandiHaler® (HH) in patients (pts) with COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013